Qiagen's CEO discussed the company's focus on specific growth drivers, while Invitae's CEO talked about pandemic-related challenges in its genetic testing business.
Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing.
Among firms presenting on the first day, 10x Genomics revealed it is developing a new high-throughput Chromium instrument, and Guardant plans to launch a comprehensive tissue sequencing assay.